Skip to main content

Table 3 Subtype analysis.

From: SHOX2 DNA Methylation is a Biomarker for the diagnosis of lung cancer based on bronchial aspirates

  Histology
Tumor Stage Adeno-carcinoma Squamous Cell Carcinoma NSCLC NOS SCLC Other/Unknown All
Stage I 10/32 (31%) 19/24 (79%) 3/3 (100%) -/- -/- 32/59 (54%)
Stage II 7/17 (41%) 20/21 (95%) 2/3 (67%) 2/2 (100%) -/- 31/43 (72%)
Stage III 20/34 (59%) 36/45 (80%) 16/22 (73%) 6/6 (100%) 1/1 (100%) 79/108 (73%)
Stage IV 12/23 (52%) 6/9 (67%) 4/8 (50%) 20/21 (95%) 0/1 (0%) 42/62 (68%)
Stage unknown 2/3 (67%) 3/4 (75%) 1/1 (100%) -/- 0/1 (0%) 6/9 (67%)
All 51/109 (47%) 84/103 (82%) 26/37 (70%) 28/29 (97%) 1/3 (33%) 190/281 (68%)
  1. Stage and histology specific performance of the SHOX2 DNA methylation biomarker in 523 bronchial aspirates from patients with suspected lung cancer.